- AU$30.65m
- AU$24.15m
- AU$4.05m
Brief: Emyria Secures Ethics Endorsement For Psilocybin-Assisted Therapy Program
Brief: Emyria Ltd Says Resignation Of Joseph Ohayon As CFO
Brief: Emyria Receives Bids Of A$2.3M To Expand Clinical Services
Brief: Emyria Seeks Trading Halt
Brief: Emyria Enters Binding Research Study Agreement With Charity Reach Wellness
Brief: Emyria Posts HY Loss Attributable A$10.8 Million
Brief: Emyria Ltd Says Health Canada Approval Received For MDMA Import
Brief: Emyria Seeks Trading Halt
Brief: Emyria Says Reached Binding Terms For Strategic Acquisition Of Pax Centre
Brief: Emyria Seeks Trading Halt
Brief: Emyria Receives firm Commitments In A Well Supported A$2.5M Placement
Brief: Emyria Ltd Seeks Trading Halt
Australia's Emyria hits 2-week high on launch of cannabis medicine
Brief: Emyria And Aspen Australia Sign Binding Licensing And Commercialisation Term Sheet
Australia's Emyria climbs as co partners with trauma psychiatric service
Brief: Emyria And Pax Centre To Develop Scalable MDMA-Assisted Therapy Model
Brief: Emyria Says Loss For Half-Year Attributable A$3.97 Mln
Brief: Emyria Completes A$3M Placement To Advance Cannabinoid Registration And MDMA-Analogue Development
Brief: Emyria Seeks Trading Halt